Cerebrovascular Disease and Interventional Neurology
Steven Messe MD, FAAN, FAHA
The management of patients with acute ischemic stroke and strategies for stroke prevention continue to evolve rapidly. Keeping abreast of advances in the field is a challenge. Several recent clinical trials will have substantial impact on stroke therapy. However, some published data are conflicting, and there are numerous remaining questions, leading to controversy regarding optimal management. Faculty will present a succinct, up-to-date, evidence-based approach to the comprehensive management of acute cerebral infarction and long-term vascular risk reduction. When an approach is unclear or unproven, faculty will discuss their experience with particular strategies. Presentations will provide concise, useful information that may be directly applied to the participant's practice. Discussions will include common yet challenging scenarios in stroke management. The session will provide ample opportunity for participants to ask questions or present their own cases to the faculty.
Participants should be knowledgeable about the optimal management of acute cerebral infarction, including patient selection for thrombolytic treatment, endovascular therapy, and surgical interventions; and develop a logical framework for implementing various long-term vascular risk reduction strategies, including selection of antithrombotic agents, lipid modifiers, antihypertensive therapies, and revascularization procedures.
Medical Knowledge, Patient Care, Practice-Based Learning and Improvement
Program Speakers - Tentative
7:00 AM - 7:05 AM
7:05 AM - 7:50 AM
Controversies in Acute Stroke
Steven R. Messe MD, FAAN, FAHA
7:50 AM - 8:35 AM
Controversies in Stroke Prevention
Tanya N. Turan MD, FAAN
8:35 AM - 9:00 AM
Questions and Cases
Steven R. Messe, MD, FAAN, FAHA
Dr. Messe has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Claret Medical, Inc. Dr. Messe has received research support from WL Gore & Associates, Bayer, and Mallinkrodt.